Month: September 2018
FSD Pharma Inc. Announces $7.5 Million Dollar at $1 Per Share Investment as Part of Existing Strategic Alliance with Auxly Cannabis Group Inc.
TORONTO, Sept. 20, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to announce that pursuant to the approved construction and development budget announced on July 3, 2018 (Link), Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”) has made an equity investment into the Company at $1.00 per Class B Subordinate
FSD Pharma Signs Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms
TORONTO, Sept.18, 2018 /PRNewswire/ – FSD Pharma Inc. (CSE: HUGE) (OTC :FSDDF ) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing
CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO, Sept. 17, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined the Cannabis Marketing Resource Center (“CMRC”) provided by Snipp Interactive Inc. (“Snipp”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and
Winnipeg, Manitoba (FSCwire) – Bird River Resources Inc. (CSE:BDR) (the “Company”) is pleased to announce that further to its news release dated June 5, 2018 the Company has received conditional approval from the Canadian Securities Exchange (the “CSE”) for its draft comprehensive CSE Form 2A 2018 Listing Statement (“Listing Statement”) and lifting of the temporary
CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO, Sept. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter
Canada’s cannabis industry is poised for explosive growth, as the country is set to legalize marijuana nationwide in the summer by July of 2018. By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than $1.3 billion, according to Health Canada estimates.
Canntab Therapeutics Ltd (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein tell Proactive Investor’s Christine Corrado the cannabis delivery manufacturing company is lining up its ducks ahead of the legalization of cannabis in Canada on October 17 this year – as it announced a profit sharing collaboration with medical pot producer FSD Pharma Inc.